Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 21,700 shares, a growth of 149.4% from the March 31st total of 8,700 shares. Based on an average daily trading volume, of 17,100 shares, the days-to-cover ratio is presently 1.3 days. Currently, 2.7% of the company’s stock are sold short.

Addex Therapeutics Trading Up 4.5 %

ADXN opened at $16.10 on Friday. Addex Therapeutics has a 12-month low of $5.00 and a 12-month high of $27.90. The business’s fifty day simple moving average is $14.55 and its 200-day simple moving average is $9.72. The company has a market capitalization of $17.07 million, a price-to-earnings ratio of -0.84 and a beta of 1.66.

Hedge Funds Weigh In On Addex Therapeutics

An institutional investor recently raised its position in Addex Therapeutics stock. Armistice Capital LLC lifted its position in shares of Addex Therapeutics Ltd (NASDAQ:ADXN) by 103.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 537,000 shares of the company’s stock after buying an additional 273,000 shares during the quarter. Armistice Capital LLC owned approximately 65.33% of Addex Therapeutics worth $206,000 at the end of the most recent quarter. 16.14% of the stock is currently owned by hedge funds and other institutional investors.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction.